Glyclada

Glyclada is a prescription medication that contains the sulfonylurea agent gliclazide as its active ingredient. It is formulated for oral administration and is marketed in the European Union. As a member of the antidiabetic therapeutic class, Glyclada works by stimulating insulin release from pancreatic beta cells. The product is intended for use under medical supervision in patients with type 2 diabetes mellitus and ongoing management.

Glyclada is indicated for the management of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

- As monotherapy in patients newly diagnosed with type 2 diabetes. - In combination with metformin when additional glucose lowering is required. - As part of a fixed‑dose combination regimen with other oral antidiabetics. - For patients who retain some endogenous insulin secretion. - To help achieve target HbA1c levels as determined by a healthcare professional.

The safety profile of Glyclada reflects the typical effects observed with sulfonylurea agents; side effects can range from mild and transient to rare but serious.

Common: - Mild to moderate hypoglycemia, presenting as shakiness, sweating, or hunger, particularly when meals are delayed. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Intermittent headache. - Dizziness or a sensation of light‑headedness, often related to low blood glucose.

Serious: - Severe hypoglycemia with confusion, seizures, or loss of consciousness requiring medical attention. - Allergic reactions including rash, itching, urticaria, or facial swelling. - Hematologic effects such as reduced white blood cells (leukopenia) or platelets (thrombocytopenia). - Hepatic abnormalities reflected by elevated liver enzymes or jaundice.

Before starting Glyclada, healthcare providers should evaluate several clinical factors to minimize risks and ensure appropriate use.

- Assess renal and hepatic function, as impairment may affect drug clearance. - Review history of cardiovascular disease, since sulfonylureas can influence cardiac outcomes. - Confirm that the patient has sufficient endogenous insulin production. - Caution in elderly patients due to increased susceptibility to hypoglycemia. - Advise patients to avoid alcohol excess, which can potentiate hypoglycemic episodes. - Discuss pregnancy and lactation status; safety data are limited.

Glyclada may interact with other medicines, altering blood glucose levels or increasing the risk of adverse effects.

Avoid: - Concomitant use with other sulfonylureas or insulin that can cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise gliclazide concentrations.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may affect glucose tolerance. - Anticoagulants, as glycemic fluctuations can influence INR stability. - Oral contraceptives, which might modify gliclazide metabolism.